

#15
MB
RECEIVED 04/29/97

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540



ROBERT GREENE STEFFE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. COHEN
DAVID K.S. CORNWELL
ROBERT W. EDMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
ANDREA G. REISTER

DANIEL N. YANNUZZI
WILLIAM C. ALLISON V
MICHAEL O. LEE
G. KEVIN TOWNSEND*
JOHN M. COVERT*
ANNE BROWN
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
STEVEN R. LUDWIG
MICHAEL V. MESSINGER
LORI L. KERBER*

JUDITH U. KIM*
KEITH KIND*
TIMOTHY J. SHEA, JR.*
DONALD R. MCPHAIL
PATRICK E. GARRETT*
NAREN R. THAPETA*
JEFFREY W. RENNECKER
BARBARA A. PARVIS
MICHAEL A. RAHMAN*
STEPHEN G. WHITESIDE*
NOEL B. WHITLEY*

DONALD J. FEATHERSTONE**
LAWRENCE B. BUGAISKY**
KAREN R. MARKOWICZ**
KIMBERLIN M. TOOHEY**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:
(202) 371-2637

INTERNET ADDRESS:

KAREN.M@SKGF.com

April 18, 1997

Assistant Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Application
Appl. No. 08/469,637; Filed: June 6, 1995
For: **HUMAN TUMOR NECROSIS FACTOR RECEPTOR**
Inventors: **GREENE et al.**
Our Ref: 1488.0710001/EKS/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. PTO Form-1449 (5 pages) with 15 references; and
3. One (1) Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents
April 18, 1997
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Karen R. Markowicz

Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

EKS:KRM:cd

Attachments

a:\0710001.tr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREENE et al.

Appl. No. 08/469,637

Filed: June 6, 1995

For: **Human Tumor Necrosis Factor Receptor**

Art Unit: 1812

Examiner: Pak, M.

Atty. Docket: 1488.0710001/EKS/KRM

First Supplemental Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 23 1997

Sir:

GROUP 1800

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the documents are also being submitted herewith. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' original Information Disclosure Statement filed on January 23, 1997, in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application.

This statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

I hereby certify that the items of information contained in the accompanying Information Disclosure Statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the accompanying Information Disclosure Statement.

It is believed that no fees are due for consideration of this First Supplemental Information Disclosure Statement. Any fees which may be due may be debited to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

Date: 4/18/97

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600